EE493 Cost-Effectiveness of Pembrolizumab+Lenvatinib for Treatment of Advanced Endometrial Carcinoma in Women Who Have Progressed Following Prior Systematic Therapy and Are Not Candidates for Curative Surgery or Radiation in France
Value in Health(2022)
Abstract
To evaluate cost-effectiveness of pembrolizumab plus lenvatinib for treatment of advanced endometrial carcinoma in women who have progressed following prior systematic therapy and are not candidate for curative surgery or radiation, from the French healthcare system perspective.
MoreTranslated text
Key words
advanced endometrial carcinoma,cost-effectiveness
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined